The metabolic syndrome and adipocytokines

FEBS Letters

Volumn 580, Issue 12, 2006, Pages 2917-2921

  Matsuzawa, Yuji ^a  

^a SUMITOMO HOSPITAL   (Japan)

Author keywords

Adipocytokine; Adiponectin; PAI 1; Visceral fat

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ADIPONECTIN; COLLAGEN; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN; PROTEIN VISFATIN; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VISFATIN;

ADIPOCYTE; ATHEROSCLEROSIS; BODY FAT DISTRIBUTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL FUNCTION; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; GENE FREQUENCY; GLUCOSE INTOLERANCE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS; RISK FACTOR; SHORT SURVEY;

ADIPONECTIN; CYTOKINES; HUMANS; INTRA-ABDOMINAL FAT; METABOLIC SYNDROME X; RISK FACTORS;

EID: 33646572904     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2006.04.028     Document Type: Short Survey

References (48)

1. Reaven G.M. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
2. Kaplan N.M. The deadly quartet. Arch. Intern. Med. 149 (1989) 1514-1520
3. DeFronzo R.A. Insulin resistance syndrome. Diabetes Care 14 (1991) 173-194
4. Matsuzawa Y.M. Pathophysiology and molecular mechanism of visceral fat syndrome: The Japanese case. Diabetes Metab. Rev. 13 (1997) 3-13
5. Despres J.P., et al. Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women. Diabetes 38 (1989) 304-309
6. Fujioka S., et al. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism. Metabolism 36 (1987) 54-59
7. Evans D.J., et al. Relationship between skeletal muscle insulin resistance, insulin-mediated glucose disposal and insulin binding: Effect of obesity and body fat topography. J. Clin. Invest. 74 (1984) 1515-1525
8. Yamashia S., et al. Insulin resistance and body fat distribution. Diabetes Care 19 (1996) 287-291
9. Kanai H., et al. Decrease in intraabdominal visceral fat may reduce blood pressure in obese hypertensive women. Hypertension 16 (1990) 484-490
10. Larson B., et al. Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death: 13 year follow up of participants in study of men born in 1913. Br. Med. J. 288 (1984) 1401-1410
11. Nakamura T., et al. Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 107 (1994) 239-246
12. Nakajima T., et al. Correlation of intraabdominal fat accumulation and left ventricular performance in obesity. Am. J. Cardiol. 163 (1994) 1107-1112
13. Shinohara E., et al. Visceral fat accumulation as an important risk factor for obstractive sleep apnea syndrome in obese subjects. J. Intern. Med. 241 (1997) 11-18
14. Matsuzawa Y., et al. Adiponectin and metabolic syndrome. Arteroscler. Thromb. Vasc. Biol. 24 (2004) 29-33
15. Uysal K., et al. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 389 (1997) 610-614
16. Shimomura I., et al. Enhanced expression of PAI-1 in visceral fat: possible contribution to vascular disease in obesity. Nat. Med. 2 (1997) 1-5
17. Matsumoto S., et al. Increased plasma HB-EGF associated with obesity and coronary artery disease. Biochem. Biophys. Res. Commun. 292 (2000) 781-786
18. Matsuzawa Y. Adipocytokines and metabolic syndrome. Seminar Vasc. Med. 5 (2005) 34-39
19. Fukuhara A., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307 (2005) 426-429
20. Maeda K., et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene ranscript 1). Biochem. Biophys. Res. Commun. 221 (1996) 286-289
21. Sherer E.P., et al. A novel serum protein similar to C1q produced exclusively in adipocytes. J. Biol. Chem. 270 (1995) 26740-26744
22. Arita Y., et al. Paradoxisal decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257 (1999) 79-83
23. Halleux C.N.M., et al. Secretion and regulation of apM1 gene expression in human visceral adipose tissue. Biochem. Biophys. Res. Commun. 288 (2001) 1102-1107
24. Maeda N., et al. PPARγ ligands increase expression and plasma concentration of adiponectin, an adipose-derived protein. Diabetes 50 (2001) 2094-2099
25. Hotta K., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscle. Thromb. Vas. Biol. 20 (2000) 1595-1599
26. Stefan N., et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation and low plasma concentration precedes a decrease in whole body insulin sensitivity in humans. Diabetes 51 (2002) 1884-1888
27. Lindsay R.S., et al. Adiponectin protects against development of type 2 diabetes in the Pima Indian population. Lancet 360 (2002) 57-58
28. Maeda N., et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. 8 (2002) 731-737
29. Tomas E., et al. Enhanced muscle fat oxidation and glucose transport by ACR30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc. Natl. Acad. Sci. USA 90 (2002) 16309-16313
30. Iwashima Y., et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 43 (2004) 1318-1323
31. Ouchi N., et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 42 (2003) 231-232
32. Ouchi N., et al. Novel modulator for endothelial adhesion molecules. Circulation 100 (1999) 2473-2476
33. Zoccali C., et al. Adiponectin, the most abundant adipocyte-derived protein, is functionally related to metabolic risk factors and predicts cardiovascular outcomes in end stage renal disease. J. Am. Soc. Nephrol. 13 (2002) 134-141
34. Kumada M., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 85-89
35. Piscon T., et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 (2004) 1730-1737
36. Kondo H., et al. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 51 (2002) 2325-2328
37. Okamoto Y., et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 26 (2002) 2767-2770
38. Matsuda M., et al. Role of adiponectin in preventing vascular stenosis: the missing link of adipo-vascular axis. J. Biol. Chem. 277 (2002) 37487-37491
39. Okamoto Y., et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascularwalls. Horm. Metab. Res. 32 (2000) 47-50
40. Ouchi N., et al. Adiponectin, adiocyte-derived plasma protein, inhibits endothelial NF-κB signaling through c-AMP dependent pathway. Circulation 102 (2000) 1296-1301
41. Arita Y., et al. Adipocyte-derived plasma protein, adiponectin, acts as a platelet derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105 (2002) 2893-2898
42. Ouchi N., et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103 (2001) 1057-1063
43. Kumada M., et al. Adiponectin specifically increases tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 109 (2004) 2046-2049
44. Shibata R., et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat. Med. 10 (2004) 1384-1389
45. Matsuzawa Y. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat. Clin. Prac. Cardiovasc. Med. 3 (2006) 42
46. Hug C., et al. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc. Natl. Acad. Sci. USA 101 (2004) 10308-10313
47. Yamauchi T., et al. Cloning of adiponectin receptors that mediate antidiabetic effects. Nature 423 (2003) 762-769
48. Nishizawa H., et al. Small heterodimer partner, an orphan nuclear receptor, augments PPARγ transactivation. J. Biol. Chem. 277 (2002) 1586-1592